Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CVM 
CEL-SCI Corp (CVM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: CVM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $240.02
1 Year Target Price $240.02
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -26.63% | Avg. Invested days 15 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 12.32M USD | Price to earnings Ratio - | 1Y Target Price 240.02 |
Price to earnings Ratio - | 1Y Target Price 240.02 | ||
Volume (30-day avg) 1 | Beta 0.26 | 52 Weeks Range 1.98 - 47.70 | Updated Date 06/29/2025 |
52 Weeks Range 1.98 - 47.70 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -12.3 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -62.86% | Return on Equity (TTM) -244.56% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 20931190 | Price to Sales(TTM) 11797.42 |
Enterprise Value 20931190 | Price to Sales(TTM) 11797.42 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.71 | Shares Outstanding 5135020 | Shares Floating 2997739 |
Shares Outstanding 5135020 | Shares Floating 2997739 | ||
Percent Insiders 1.2 | Percent Institutions 5.07 |
Analyst Ratings
Rating 1 | Target Price 240.02 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
CEL-SCI Corp
Company Overview
History and Background
CEL-SCI Corp is a biotechnology company focused on researching and developing immune system-based therapies for the treatment of cancer and other diseases. Founded in 1983, the company has primarily focused on its lead investigational therapy, Multikine.
Core Business Areas
- Immunotherapy Development: Focused on the development and commercialization of cancer immunotherapies, primarily Multikine (Leukocyte Interleukin, Injection) for the treatment of head and neck cancer.
Leadership and Structure
Geert Kersten serves as the Chief Executive Officer of CEL-SCI Corp. The company operates with a standard corporate structure, including a board of directors and various departments focused on research and development, clinical trials, and regulatory affairs.
Top Products and Market Share
Key Offerings
- Multikine (Leukocyte Interleukin, Injection): Multikine is CEL-SCI's lead investigational therapy, designed as a neoadjuvant immunotherapy for treatment-naive advanced primary head and neck cancer. It is not yet approved. Competitors include Merck (Keytruda), Bristol Myers Squibb (Opdivo), and various chemotherapy regimens.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by intense competition, high research and development costs, and a complex regulatory environment. Cancer immunotherapy is a rapidly growing field with significant potential.
Positioning
CEL-SCI is positioned as a company focused on developing novel immunotherapy treatments for cancer. Their competitive advantage, if proven effective, would lie in Multikine's novel approach and potential to improve patient outcomes. Their clinical trial data remains under scrutiny.
Total Addressable Market (TAM)
The global head and neck cancer market is projected to reach billions of dollars. CEL-SCI aims to capture a portion of this market with Multikine, if approved.
Upturn SWOT Analysis
Strengths
- Proprietary immunotherapy technology
- Experienced management team
- Focused on unmet medical needs
Weaknesses
- Limited financial resources
- Reliance on a single product candidate (Multikine)
- Past clinical trial setbacks and controversies
- No FDA approved products
Opportunities
- Potential FDA approval of Multikine
- Expansion into other cancer indications
- Partnerships with larger pharmaceutical companies
Threats
- Regulatory hurdles and clinical trial failures
- Competition from established pharmaceutical companies
- Patent expiration
- Adverse reactions from Multikine
Competitors and Market Share
Key Competitors
- MRK
- BMY
- PFE
Competitive Landscape
CEL-SCI faces significant competition from large pharmaceutical companies with established immunotherapy products and greater resources. Its success depends on demonstrating a clear clinical benefit with Multikine.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been primarily driven by investment in research and development, with no significant product revenue to date.
Future Projections: Future growth is contingent on the successful development and commercialization of Multikine or other pipeline candidates. Analyst projections are speculative and highly dependent on regulatory approvals.
Recent Initiatives: Recent initiatives have focused on addressing regulatory inquiries and seeking potential partnerships.
Summary
CEL-SCI Corp is a high-risk, high-reward biotechnology company focused on developing Multikine. Its future hinges on successful clinical trials and regulatory approval. The company's lack of product revenue and reliance on a single candidate presents significant risks. Strong strategic partnerships or acquisition may be key to long-term viability.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC filings
- Company website
- Third-party financial data providers
- Industry reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CEL-SCI Corp
Exchange NYSE MKT | Headquaters Vienna, VA, United States | ||
IPO Launch date 1987-01-01 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://cel-sci.com |
Full time employees - | Website https://cel-sci.com | ||
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. In addition, the company's LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.